take
account
sarscoronaviru
also
know
spread
invas
critic
period
lack
therapeut
drug
antivir
vaccin
necessari
us
research
discuss
new
therapeut
devic
quickli
defin
agent
convent
use
could
offer
true
clinic
benefit
interest
statin
inexpens
readili
avail
easili
toler
drug
use
reduc
morbid
mortal
caus
influenza
viral
diseas
provid
numer
scientif
public
past
year
reason
never
gone
deep
statin
inhibitor
hmgcoa
reductas
enzym
limit
pathway
mevalon
cholesterol
pleiotrop
effect
describ
sever
public
especi
themat
issu
statin
new
life
old
drug
publish
pharmacol
re
collabor
discover
compound
prof
endo
substanc
antiinflammatori
immunomodulatori
effect
could
certainli
benefit
patient
influenza
viral
patholog
experiment
evid
suggest
effect
statin
viral
infect
potenti
mechan
action
tabl
virus
statininduc
reduct
cholesterol
plasma
membran
result
lower
viral
titr
failur
intern
viru
data
suggest
virus
cholesterol
affect
earli
stage
infect
particular
initi
stage
infect
virus
bind
specif
receptor
concentr
within
lipid
raft
area
plasma
membran
rich
cholesterol
statin
reduc
percentag
cholesterol
present
membran
alter
assembl
receptor
dramat
reduc
possibl
adhes
viral
agent
host
lipid
raft
also
involv
viral
replic
phase
constitut
packet
vesicl
capabl
concentr
viru
replic
factor
process
also
highli
destabil
statin
mani
viral
pathogen
encod
substrat
mammalian
prenyl
pathway
mevalon
pathway
hypothes
predil
viral
protein
benefici
propag
viru
viral
infect
statin
inhibit
hmgcoar
reduc
express
prenyl
protein
carri
evid
antivir
activ
recent
studi
shown
influenza
viru
induc
format
numer
lipid
droplet
infect
cell
experiment
model
use
madindarbi
dog
kidney
cell
treat
atorvastatin
atv
induc
infect
pretreat
reduc
j
u
r
n
l
p
r
e
p
r
f
infecti
capac
consequ
product
new
influenza
virus
percentag
higher
studi
perform
viral
strain
shown
differ
statin
perform
antivir
activ
variabl
efficaci
probabl
due
specif
pharmacolog
biochem
properti
statin
use
analysi
therefor
differ
antivir
power
observ
furthermor
besid
statin
also
seri
mevalon
pathway
inhibitor
could
use
next
futur
specif
target
effect
certainli
worth
studi
detail
mechan
statin
inhibit
viru
replic
although
unsuit
prophylaxi
patient
studi
efficaci
antivir
vitro
could
provid
valuabl
tool
identifi
mechan
action
prevent
viru
reproduct
therefor
pandem
spread
hypothes
strongli
support
substanti
metaanalyz
retrospect
studi
show
reduc
hospit
rate
mortal
subject
alreadi
user
statin
affect
flu
diseas
cours
studi
need
evalu
cellular
anim
model
direct
effect
statin
differ
viral
strain
anyth
coronaviru
obvious
follow
clinic
studi
larg
dictat
current
clinic
emerg
analysi
interact
statin
virus
high
cost
health
social
repres
valuabl
possibl
also
consid
effect
statin
famili
member
coronaviridia
never
investig
posit
result
studi
could
provid
health
servic
effect
safe
lowcost
tool
improv
prognosi
viral
patholog
prevent
pandem
improv
antivir
prophylaxi
frail
patient
conclus
letter
want
draw
attent
research
physician
therapeut
perspect
yet
fulli
investig
human
hepatocarcinoma
cell
contain
subgenom
hcv
replicon
dosedepend
inhibit
hcv
replicon
replic
measur
luciferas
signal
addit
antivir
activ
shortterm
use
combin
hcv
nonstructur
ns
polymeras
proteas
inhibitor
